MINUTES

CPIC CONFERENCE CALL

DATE: February 6, 2012

PRESENT: Adriana Malheiro, Andrea Gaedigk, Caroline Thorn, Deanna Kroetz, Issam Zineh, Kristine Crews, Mary Relling, Michelle Carrillo, Nita Limdi, Min Song, Russell Wilke, Stuart Scott, Teri Klein, Todd Skaar, James Hoffman, Daniel Mueller.

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Updates on guidelines in progress. | General comments on timing: best to get them done on a shorter time scale than a longer time scale, or momentum is lost.  General comments on CPIC guideline updates: when first guidelines are substantially updated on PharmGKB, probably should write a piece for CPT noting the update.  a. HLA/Carbamazepine—Susan Leckband---mid January---  have completed the rough draft of the CBZ + HLA-B\*15:02 guidelines and supplement and will be able to send it to CPIC for review later this week or next at the latest.  b. HLA/allopurinol—Michael Lee--- discussed in a TC about 2 weeks ago  c. SLC01B1/statins---Russ Wilke---  Near final draft posted on CPIC site. Feedback sent to Russ by several CPIC members. SLCO1B1 haplotypes updated on PharmGKB.  d. 2D6/2C19/TCAs---Swen/Hicks--- mid January for 1st draft  circulated draft Table 2, allowing for actions based on CYP2D6 alone, CYP2C19 alone, and combination of 2 genes. Daniel Mueller offered to help.  e. DPYD/fluoropyrimidines—Howard McLeod--- some work under way; working with Caroline Thorn.  f. 2D6 antidepressants—Susan Leckband  Focus is on SSRIs and 2D6 + venlafaxine.  Next teleconference will be on Monday, 2/13/12@0900 PST.    g. IL28B/interferon --- Andrew Muir  Little progress but getting going. Additional offers of help from Glenn Gerhard and Dave Nelson.  a. | Teri and PharmGKB staff will work with authors on setting deadlines.  First updates will need to be formally noted with CPT help.  Susan to circulate near final draft to CPIC in early February.  Michael hopes to have revision next week.  Russ will modify and send to CPT.  Jesse and Kevin getting additional clinician input on Table 1.  Still hope for draft in March.  Anticipates completing the rough drafts within the next few months  Andrew plans to get under way soon. |
| Importance of Table 1 | The importance of translating CPIC guidelines into “look-up tables,” that link diplotypes and into phenotypes, was discussed. These phenotype designations are important for annotating specific dosing recommendations, and will be used by sites who are doing clinical implementation (e.g. including the TPP sites). The listings of diplotypes should be as detailed as possible to permit translation of diplotype result from lab into actions.  In addition, where possible, “universal” phenotypic terms (e.g. extensive, intermediate, poor metabolizer) should be used across genes. This will facilitate medical coding, development of universal diagnostic codes (e.g. ICD-10, SNOMED) that can be used in medical records. It was noted that using “universal” phenotype designations would also facilitate annotations in the GTR. | Authors should (1) make their designations of alleles as detailed as possible, using the supplement if needed to capture all alleles that may be reported from clinical labs and (2) use “universal” phenotypic terms when possible.  The group will consider writing a review describing those phenotypic terms when applicable. |
| ASHP endorsement | James reported that ASHP formally approved CPIC clopidogrel guidelines. | They are working through one guideline at a time; will link to their endorsement on ASHP site when fully public. |
| CYP2D6/codeine guideline is out! | <http://www.ncbi.nlm.nih.gov/pubmed/22205192> | none |
| Submission to guidelines.gov | Marc Williams brought up and we discussed earlier suggestions to submit CPIC guidelines to guidelines.gov. This would take some administrative and formatting work. | Rochelle Long volunteered to look into whether there might be some resources available to accomplish this. |
| GTR | Dr. Malheiro indicated GTR is going live in ~ 2 weeks. She had a conference call with Rochelle, Teri, Mary, Julie, and Stuart, at which recommendations on wording were made, and CPIC suggested that the GTR utilize CPIC to review content of GTR posts and link to PharmGKB/CPIC content for gene/drug information. She also had usability session with Stuart Scott and volunteered to have others (Uli Broeckel expressed interest). ARUP/warfarin will be first pharmacogenetic test on GTR. Donna McGLock should be communicating with PharmGKB about linking to CPIC and other PharmGKB content on clinical pharmacogenetic tests. | Adriana welcomes feedback from CPIC members. CPIC encourages GTR to link to CPIC guidelines where possible for pharmacogenetic test information.  Adriana will do web demo of GTR on upcoming CPIC call. |
| How to write a CPIC guideline | Ran out of time. Slides available on CPIC site. <http://consortia.pharmgkb.org/display/cpic/Files> | Will cover in upcoming meeting; guideline authors who want a refresher should contact Mary. |